Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Biogen Stock Rating Upgraded Amid Positive Data From Alzheimer's ...

📈 Truist Securities upgraded Biogen to Buy and raised its price target to $235 from $190 ahead of the study readout.

🧬 Diranersen (BIIB080) is an investigational antisense oligonucleotide designed to lower tau protein production in Alzheimer's disease.

📊 The Phase 2 CELIA trial enrolled 416 patients with mild cognitive impairment or mild Alzheimer's dementia.

⚠️ The study missed its primary endpoint regarding dose-dependent effects on the Clinical Dementia Rating–Sum of Boxes at Week 76.

✅ Secondary analyses showed slowed clinical decline across all doses, with the strongest signal observed at the lowest 60 mg dose.

🧪 Significant reductions in tau were measured in spinal fluid and on brain scans during the trial period.

📅 Biogen has moved diranersen into registrational development to support a future approval application.

💊 Leqembi remains the only FDA-approved Biogen Alzheimer's treatment, targeting amyloid rather than tau.

🏥 Real-world LEADER study data shows 76% of patients on Leqembi stayed stable and 7% improved over an average of 17 months.

💉 A new under-the-skin starting dose for Leqembi is under FDA Priority Review with a decision expected by August 24, 2026.

Bullish Signals
  • Analyst upgrades from Truist and Guggenheim reflect strong investor confidence in the company's pipeline following the CELIA trial data.
  • Diranersen demonstrated slowed clinical decline across all tested doses, indicating potential efficacy in delaying disease progression.
  • The drug achieved large reductions in tau biomarkers in both spinal fluid and brain scans, validating its mechanism of action.
  • Biogen has successfully advanced diranersen into registrational development, a critical milestone for future FDA approval.
Risk Factors
  • The CELIA trial failed to meet its primary endpoint of showing a dose-dependent effect on cognitive function at Week 76.
  • Diranersen remains an investigational drug that requires successful completion of Phase 3 trials before any regulatory approval can be granted.
  • Secondary findings cannot substitute for hitting the main target, meaning the drug's commercial viability is not yet confirmed.
Full Analysis
Biogen (BIIB) stock received analyst upgrades following positive secondary data from its investigational tau-targeting drug, diranersen (BIIB080). Truist Securities upgraded the rating to Buy with a price target of $235, while Guggenheim maintained a Buy rating with a $260 target. The optimism stems from a Phase 2 trial called CELIA where patients showed slowed clinical decline and reduced tau levels in spinal fluid and brain scans across all tested doses. Despite the positive secondary signals, the study missed its primary endpoint of demonstrating a dose-dependent effect on cognitive function measured by the CDR-SB scale at Week 76. Consequently, diranersen remains an investigational therapy requiring completion of registrational Phase 3 trials and FDA approval before it can be marketed. The data was presented at the AAIC conference, highlighting that while the drug shows biological activity, it has not yet secured regulatory clearance for Alzheimer's treatment. The article clarifies that this news does not impact currently available Biogen treatments like Leqembi (lecanemab), which targets amyloid rather than tau and is already FDA-approved. Real-world data from the LEADER study indicates that approximately 76% of early-Alzheimer's patients on Leqembi remained stable over 17 months, with a new under-the-skin formulation currently under Priority Review for an August 2026 decision.